{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T11:34:19Z","timestamp":1772969659918,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,12,15]],"date-time":"2017-12-15T00:00:00Z","timestamp":1513296000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s00702-017-1830-8","type":"journal-article","created":{"date-parts":[[2017,12,15]],"date-time":"2017-12-15T12:56:36Z","timestamp":1513342596000},"page":"1355-1360","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson\u2019s disease"],"prefix":"10.1007","volume":"125","author":[{"given":"Adjia","family":"Hamadjida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen G.","family":"Nuara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jim C.","family":"Gourdon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Huot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,12,15]]},"reference":[{"key":"1830_CR1","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJM199307153290303","volume":"329","author":"JM Alvir","year":"1993","unstructured":"Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA (1993) Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 329:162\u2013167","journal-title":"N Engl J Med"},{"key":"1830_CR2","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/(SICI)1098-2396(199612)24:4<349::AID-SYN5>3.0.CO;2-D","volume":"24","author":"CR Ashby Jr","year":"1996","unstructured":"Ashby CR Jr, Wang RY (1996) Pharmacological actions of the atypical antipsychotic drug clozapine: a review. Synapse 24:349\u2013394","journal-title":"Synapse"},{"key":"1830_CR3","first-page":"213","volume":"77","author":"G Cerone","year":"1977","unstructured":"Cerone G, Ruggieri S, Agnoli A (1977a) Parkinsonian tremor: a neuropharmacological study. Acta Neurol Belg 77:213\u2013229","journal-title":"Acta Neurol Belg"},{"key":"1830_CR4","first-page":"354","volume":"53","author":"G Cerone","year":"1977","unstructured":"Cerone G, Ruggieri S, Aloisi P, Cappenberg L, Agnoli A (1977b) Pharmacological study of parkinsonian tremor. III. Role of the serotonin-histamine system. Boll Soc Ital Biol Sper 53:354\u2013360","journal-title":"Boll Soc Ital Biol Sper"},{"key":"1830_CR5","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1124\/jpet.102.034686","volume":"302","author":"AM Crissman","year":"2002","unstructured":"Crissman AM, O\u2019Donnell JM (2002) Effects of antidepressants in rats trained to discriminate centrally administered isoproterenol. J Pharmacol Exp Ther 302:606\u2013611","journal-title":"J Pharmacol Exp Ther"},{"key":"1830_CR6","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","volume":"383","author":"J Cummings","year":"2014","unstructured":"Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, Dhall R, Ballard C (2014) Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 383:533\u2013540","journal-title":"Lancet"},{"key":"1830_CR7","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1212\/01.WNL.0000110317.52453.6C","volume":"62","author":"F Durif","year":"2004","unstructured":"Durif F, Debilly B, Galitzky M, Morand D, Viallet F, Borg M, Thobois S, Broussolle E, Rascol O (2004) Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 62:381\u2013388","journal-title":"Neurology"},{"key":"1830_CR8","first-page":"629","volume":"14","author":"M El-Awar","year":"1987","unstructured":"El-Awar M, Freedman M, Seeman P, Goldenberg L, Little J, Solomon P (1987) Response of tardive and l-DOPA-induced dyskinesias to antidepressants. Can J Neurol Sci 14:629\u2013631","journal-title":"Can J Neurol Sci"},{"key":"1830_CR9","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1001\/archneur.63.9.1343","volume":"63","author":"SH Fox","year":"2006","unstructured":"Fox SH, Visanji NP, Johnston TH, Gomez-Ramirez J, Voon V, Brotchie JM (2006) Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease. Arch Neurol 63:1343\u20131344","journal-title":"Arch Neurol"},{"key":"1830_CR10","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1017\/S0317167100009707","volume":"37","author":"SH Fox","year":"2010","unstructured":"Fox SH, Visanji N, Reyes G, Huot P, Gomez-Ramirez J, Johnston T, Brotchie JM (2010) Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson\u2019s disease. Can J Neurol Sci 37:86\u201395","journal-title":"Can J Neurol Sci"},{"key":"1830_CR11","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/S0140-6736(99)00860-0","volume":"353","author":"French Clozapine Parkinson Study Group","year":"1999","unstructured":"French Clozapine Parkinson Study Group (1999) Clozapine in drug-induced psychosis in Parkinson\u2019s disease. The French Clozapine Parkinson Study Group. Lancet 353:2041\u20132042","journal-title":"Lancet"},{"key":"1830_CR12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/mds.21226","volume":"22","author":"CG Goetz","year":"2007","unstructured":"Goetz CG, Damier P, Hicking C, Laska E, Muller T, Olanow CW, Rascol O, Russ H (2007) Sarizotan as a treatment for dyskinesias in Parkinson\u2019s disease: a double-blind placebo-controlled trial. Mov Disord 22:179\u2013186","journal-title":"Mov Disord"},{"key":"1830_CR14","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00213-017-4530-z","volume":"234","author":"A Hamadjida","year":"2017","unstructured":"Hamadjida A, Nuara SG, Veyres N, Frouni I, Kwan C, Sid-Otmane L, Harraka MJ, Gourdon JC, Huot P (2017) The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset. Psychopharmacology 234:905\u2013911","journal-title":"Psychopharmacology"},{"key":"1830_CR13","doi-asserted-by":"crossref","unstructured":"Hamadjida A, Nuara SG, Gourdon JC, Huot P (2018) The effect of mianserin on the severity of psychosis and dyskinesia in the parkinsonian marmoset. Prog Neuropsychopharmacol Biol Psychiatry 81:367\u2013371","DOI":"10.1016\/j.pnpbp.2017.09.001"},{"key":"1830_CR15","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/mds.20324","volume":"20","author":"MA Hely","year":"2005","unstructured":"Hely MA, Morris JG, Reid WG, Trafficante R (2005) Sydney Multicenter Study of Parkinson\u2019s disease: non-l-DOPA-responsive problems dominate at 15\u00a0years. Mov Disord 20:190\u2013199","journal-title":"Mov Disord"},{"key":"1830_CR16","doi-asserted-by":"crossref","first-page":"7190","DOI":"10.1523\/JNEUROSCI.1171-11.2011","volume":"31","author":"P Huot","year":"2011","unstructured":"Huot P, Johnston TH, Lewis KD, Koprich JB, Reyes MG, Fox SH, Piggott MJ, Brotchie JM (2011) Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of on-time. J Neurosci 31:7190\u20137198","journal-title":"J Neurosci"},{"key":"1830_CR17","doi-asserted-by":"crossref","first-page":"e45587","DOI":"10.1371\/journal.pone.0045587","volume":"7","author":"P Huot","year":"2012","unstructured":"Huot P, Johnston TH, Gandy MN, Reyes MG, Fox SH, Piggott MJ, Brotchie JM (2012a) The monoamine re-uptake inhibitor UWA-101 improves motor fluctuations in the MPTP-lesioned common marmoset. PLoS One 7:e45587","journal-title":"PLoS One"},{"key":"1830_CR18","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1124\/jpet.112.195693","volume":"342","author":"P Huot","year":"2012","unstructured":"Huot P, Johnston TH, Koprich JB, Aman A, Fox SH, Brotchie JM (2012b) l-745,870 reduces l-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson\u2019s disease. J Pharmacol Exp Ther 342:576\u2013585","journal-title":"J Pharmacol Exp Ther"},{"key":"1830_CR19","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.neuropharm.2014.01.012","volume":"82","author":"P Huot","year":"2014","unstructured":"Huot P, Johnston TH, Lewis KD, Koprich JB, Reyes MG, Fox SH, Piggott MJ, Brotchie JM (2014) UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances l-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset. Neuropharmacology 82:76\u201387","journal-title":"Neuropharmacology"},{"key":"1830_CR20","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1124\/jpet.106.110429","volume":"319","author":"MM Iravani","year":"2006","unstructured":"Iravani MM, Tayarani-Binazir K, Chu WB, Jackson MJ, Jenner P (2006) In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with increased motor disability. J Pharmacol Exp Ther 319:1225\u20131234","journal-title":"J Pharmacol Exp Ther"},{"key":"1830_CR21","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1096\/fj.11-195016","volume":"26","author":"TH Johnston","year":"2012","unstructured":"Johnston TH, Millar Z, Huot P, Wagg K, Thiele S, Salomonczyk D, Yong-Kee CJ, Gandy MN, McIldowie M, Lewis KD, Gomez-Ramirez J, Lee J, Fox SH, Martin-Iverson M, Nash JE, Piggott MJ, Brotchie JM (2012) A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances l-DOPA benefit in parkinsonian primates. FASEB J 26:2154\u20132163","journal-title":"FASEB J"},{"key":"1830_CR22","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.parkreldis.2012.07.001","volume":"19","author":"TH Johnston","year":"2013","unstructured":"Johnston TH, Huot P, Damude S, Fox SH, Jones SW, Rusche JR, Brotchie JM (2013) RGFP109, a histone deacetylase inhibitor attenuates l-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: a proof-of-concept study. Parkinsonism Relat Disord 19:260\u2013264","journal-title":"Parkinsonism Relat Disord"},{"key":"1830_CR23","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1212\/WNL.0b013e31825f0451","volume":"79","author":"PA Lewitt","year":"2012","unstructured":"Lewitt PA, Hauser RA, Lu M, Nicholas AP, Weiner W, Coppard N, Leinonen M, Savola JM (2012) Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study). Neurology 79:163\u2013169","journal-title":"Neurology"},{"key":"1830_CR24","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/BF00215475","volume":"92","author":"P Mason","year":"1987","unstructured":"Mason P, Skinner J, Luttinger D (1987) Two tests in rats for antianxiety effect of clinically anxiety attenuating antidepressants. Psychopharmacology 92:30\u201334","journal-title":"Psychopharmacology"},{"key":"1830_CR25","first-page":"377","volume":"11","author":"F Mastrosimone","year":"1980","unstructured":"Mastrosimone F, Colucci d\u2019Amato C, De Angelis G, Iaccarino C, Giordano L, Marmo E (1980) Personal experience with a combination of drugs in subjects with dopa resistant Parkinson\u2019s disease. J Med 11:377\u2013383","journal-title":"J Med"},{"key":"1830_CR26","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0022-3565(24)37161-7","volume":"283","author":"MJ Owens","year":"1997","unstructured":"Owens MJ, Morgan WN, Plott SJ, Nemeroff CB (1997) Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 283:1305\u20131322","journal-title":"J Pharmacol Exp Ther"},{"key":"1830_CR27","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199903113401003","volume":"340","author":"Parkinson Study Group","year":"1999","unstructured":"Parkinson Study Group (1999) Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease. The Parkinson Study Group. N Engl J Med 340:757\u2013763","journal-title":"N Engl J Med"},{"key":"1830_CR28","first-page":"621","volume":"96","author":"GL Piccinin","year":"1981","unstructured":"Piccinin GL, Piccirilli M, Agostini L (1981) Treatment of parkinson disease with the combination of l-DOPA (plus carbidopa) and trazodone. Clin Ter 96:621\u2013626","journal-title":"Clin Ter"},{"key":"1830_CR29","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0022-3565(25)21446-X","volume":"230","author":"E Richelson","year":"1984","unstructured":"Richelson E, Nelson A (1984) Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther 230:94\u2013102","journal-title":"J Pharmacol Exp Ther"},{"key":"1830_CR30","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1006\/phrs.2000.0790","volume":"43","author":"R Rudissaar","year":"2001","unstructured":"Rudissaar R, Pruus K, Vaarmann A, Pannel P, Skrebuhhova-Malmros T, Allikmets L, Matto V (2001) Acute trazodone and quipazine treatment attenuates apomorphine-induced aggressive behaviour in male rats without major impact on emotional behaviour or monoamine content post mortem. Pharmacol Res 43:349\u2013358","journal-title":"Pharmacol Res"},{"key":"1830_CR31","first-page":"344","volume":"53","author":"S Ruggieri","year":"1977","unstructured":"Ruggieri S, Cerone G, Aloisi P, Cappenberg L, Agnoli A (1977) Pharmacological study of parkinsonian tremor. I. Methods. Boll Soc Ital Biol Sper 53:344\u2013348","journal-title":"Boll Soc Ital Biol Sper"},{"key":"1830_CR32","first-page":"358","volume":"56","author":"F Sanson","year":"1986","unstructured":"Sanson F, Schergna E, Semenzato D, Trevisan CP, Bizzarini M, Violante F, Santagostino I, Ravenna C, Maccarone G (1986) Therapeutic effects of trazodone in the treatment of tremor. Multicentric double-blind study. Riv Neurol 56:358\u2013364","journal-title":"Riv Neurol"},{"key":"1830_CR33","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1093\/brain\/awu409","volume":"138","author":"P Svenningsson","year":"2015","unstructured":"Svenningsson P, Rosenblad C, Af Edholm Arvidsson K, Wictorin K, Keywood C, Shankar B, Lowe DA, Bjorklund A, Widner H (2015) Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson\u2019s disease: a dose-finding study. Brain 138:963\u2013973","journal-title":"Brain"},{"key":"1830_CR34","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.pbb.2008.04.010","volume":"90","author":"KE Vanover","year":"2008","unstructured":"Vanover KE, Betz AJ, Weber SM, Bibbiani F, Kielaite A, Weiner DM, Davis RE, Chase TN, Salamone JD (2008) A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model. Pharmacol Biochem Behav 90:540\u2013544","journal-title":"Pharmacol Biochem Behav"},{"key":"1830_CR35","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/mds.21073","volume":"21","author":"NP Visanji","year":"2006","unstructured":"Visanji NP, Gomez-Ramirez J, Johnston TH, Pires D, Voon V, Brotchie JM, Fox SH (2006) Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson\u2019s disease. Mov Disord 21:1879\u20131891","journal-title":"Mov Disord"},{"key":"1830_CR36","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1590\/S0004-282X2009000300007","volume":"67","author":"AL Werneck","year":"2009","unstructured":"Werneck AL, Rosso AL, Vincent MB (2009) The use of an antagonist 5-HT2a\/c for depression and motor function in Parkinson\u2019 disease. Arq Neuropsiquiatr 67:407\u2013412","journal-title":"Arq Neuropsiquiatr"},{"key":"1830_CR37","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.pharmthera.2017.04.004","volume":"178","author":"K Yanai","year":"2017","unstructured":"Yanai K, Yoshikawa T, Yanai A, Nakamura T, Iida T, Leurs R, Tashiro M (2017) The clinical pharmacology of non-sedating antihistamines. Pharmacol Ther 178:148\u2013156","journal-title":"Pharmacol Ther"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-017-1830-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-017-1830-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-017-1830-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T21:28:48Z","timestamp":1751146128000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-017-1830-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,15]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["1830"],"URL":"https:\/\/doi.org\/10.1007\/s00702-017-1830-8","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,15]]}}}